Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
NCT04334460
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Sars-CoV-2
Covid19
Interventions
DRUG:
BLD-2660
Sponsor
Blade Therapeutics
Collaborators
[object Object]